|
|
|
|
|
 |
4 |
 |
| |

HOPE-2: Baseline characteristics
|
|
 |
|
 |
|
 |
5 |
 |
| |

HOPE-2: Baseline prevalence of CV risk factors
|
|
 |
|
 |
|
 |
6 |
 |
| |

HOPE-2: Baseline prevalence of CVD
|
|
 |
|
 |
|
 |
7 |
 |
| |

HOPE-2: Baseline medication use
|
|
 |
|
 |
|
 |
8 |
 |
| |

HOPE-2: Change in plasma homocysteine over time
|
|
 |
|
 |
|
 |
9 |
 |
| |

HOPE-2: Primary outcome shows no benefit of vitamin supplementation
|
|
 |
|
 |
|
 |
10 |
 |
| |

HOPE-2: Primary outcome and components
|
|
 |
|
 |
|
 |
11 |
 |
| |

HOPE-2: Secondary outcome and components
|
|
 |
|
 |
|
|